BETA
Your AI-Trained Oncology Knowledge Connection!
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
Advances in NSCLC Bring Excitement in the Lung Space
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC
The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.
Taletrectinib Shows Positive Efficacy and Toxicity in ROS1+ NSCLC
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
Busulfan-Enhanced VRD Regimen Improves Efficacy in NDMM
Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.
Unveiling Advances in GU Cancers: Insights from Oncology Decoded
Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.
Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer
Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.
Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL
The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.
Video-Based Genetic Counseling Improves Comprehension in HBOC
In those being screened for hereditary breast and ovarian cancer syndrome, use of a video tool improved the duration of physician-led genetic counseling.
Taletrectinib is Suitable for First- and Second-Line ROS1+ NSCLC
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma
The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.
3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer
Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.
Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma
Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.
SonoClear System Earns Breakthrough Designation for Intracranial Procedures
The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.
Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC
Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.
Increasing Clinician Awareness of PIPAC May Help Increase Its Use
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia
The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.
PIPAC Is Minimally Invasive and Tolerable in Peritoneal Carcinomatosis
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma
A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.
AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer
Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.
High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL
Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma
89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.
Serplulimab Earns UK Approval in Extensive-Stage Small Cell Lung Cancer
Data from the phase 3 ASTRUM-005 trial support the MHRA’s approval of serplulimab for patients with extensive-stage small cell lung cancer.
Early Efficacy Seen With Gedatolisib-Based Therapies in Prostate/Breast Cancers
Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.
Exercise-Based Regimen Shows Efficacy Promise in CRC
Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.
